Target Name: WASF3
NCBI ID: G10810
Review Report on WASF3 Target / Biomarker Content of Review Report on WASF3 Target / Biomarker
WASF3
Other Name(s): Wiskott-Aldrich syndrome protein family member 3 (isoform 1) | SCAR3 | verprolin homology domain-containing protein 3 | WAS protein family member 3 | Verprolin homology domain-containing protein 3 | WASF3 variant 1 | WASP family member 3 | WASF3_HUMAN | Brush-1 | Protein WAVE-3 | WASP family Verprolin-homologous protein 3 | Wiskott-Aldrich syndrome protein family member 3 | WASP family protein member 3 | WAVE3 | KIAA0900 | protein WAVE-3 | Actin-binding protein WASF3

WASF3: Implicated in Autoimmune Diseases

WASF3 (Wiskott-Aldrich syndrome protein family member 3) is a protein that is expressed in various tissues of the body, including the brain, spleen, heart, and lymphoid organs. It is a member of the WASF3 gene family, which is known for the development of various autoimmune diseases, including WASF3-associated autoimmune neuropathy (WASF3-AN) and systemic lupus erythematosus (SLE).

WASF3 is a 18-kDa protein that is expressed in the brain, spleen, heart, and lymphoid organs. It is highly conserved and has a predicted localization in the brain, specifically in the diencephalon, where it is expressed in the peri-axonal neurons and in the choroid plexus. WASF3 is also expressed in various other tissues, including the spleen, heart, and lymphoid organs.

The WASF3 gene has been implicated in the development of various autoimmune diseases, including WASF3-associated autoimmune neuropathy (WASF3-AN) and systemic lupus erythematosus (SLE). WASF3-AN is a progressive neurodegenerative disorder that is characterized by the progressive loss of pericytes in the brain, which are the glial cells that support the nervous system. WASF3-AN is also associated with the development of various neuropathies, including optic neuritis, neurofibromatosis, and multiple sclerosis.

WASF3 has also been shown to be involved in the development and progression of SLE, an autoimmune disease that can affect various organs and systems in the body. SLE is characterized by the production of autoantibodies, which can cause inflammation and damage to various tissues. WASF3 has been shown to be involved in the development and progression of SLE by regulating the activity of various immune cells and promoting the production of autoantibodies.

In addition to its involvement in autoimmune diseases, WASF3 has also been shown to be involved in various physiological processes in the body. For example, WASF3 has been shown to be involved in the regulation of inflammation, cell survival, and cell proliferation. It has also been shown to play a role in the regulation of pain perception and neurotransmitter release.

Despite the potential involvement of WASF3 in various autoimmune diseases, the precise function of the protein is not well understood. However, several studies have shown that WASF3 is involved in the regulation of inflammation and immune cell function.

In conclusion, WASF3 is a protein that is involved in various physiological processes in the body and has been implicated in the development and progression of various autoimmune diseases. Further research is needed to fully understand the function of WASF3 and its potential as a drug target or biomarker.

Protein Name: WASP Family Member 3

Functions: Downstream effector molecules involved in the transmission of signals from tyrosine kinase receptors and small GTPases to the actin cytoskeleton. Plays a role in the regulation of cell morphology and cytoskeletal organization. Required in the control of cell shape

The "WASF3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WASF3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P | WASH6P | WASH7P | WASH8P | WASHC1 | WASHC2A | WASHC2C | WASHC3 | WASHC4 | WASHC5 | WASIR1 | WASL | WAVE1 complex | WBP1 | WBP11 | WBP11P1 | WBP1L | WBP2 | WBP2NL | WBP4 | WDCP | WDFY1 | WDFY2 | WDFY3 | WDFY3-AS2 | WDFY4 | WDHD1 | WDPCP | WDR1 | WDR11 | WDR11-DT | WDR12 | WDR13 | WDR17 | WDR18 | WDR19 | WDR20 | WDR24 | WDR25 | WDR26 | WDR27 | WDR3 | WDR31 | WDR33 | WDR35 | WDR35-DT | WDR36 | WDR37 | WDR38 | WDR4 | WDR41 | WDR43 | WDR44 | WDR45 | WDR45B | WDR46 | WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2